Introduction to Myeloma
News
Multiple Myeloma Q&A
Testimonials
Press Releases
Resources
Biography
Resume
Contact
Subscribe:
Posts
|
Comments
James R. Berenson, MD, Inc.
Berenson Oncology
Introduction to Myeloma
News
Multiple Myeloma Q&A
Testimonials
Press Releases
Resources
Biography
Resume
Contact
Archive | Broadcasts
RSS feed for this section
Full Show: A New BCMA Test to Track Multiple Myeloma Levels with Dr. James R. Berenson, MD, IMBCR
February 22, 2016
0 Comments
…
Article
Continue reading...
IMBCR – KTLA 5 News – Segment 3
March 6, 2014
0 Comments
…
Article
Continue reading...
IMBCR – KTLA 5 News – Segment 2
March 6, 2014
0 Comments
…
Article
Continue reading...
←
More posts
James R. Berenson, MD
President & CEO, Institute for Myeloma & Bone Cancer Research (IMBCR)
President & Medical Director. Berenson Cancer Center (Berensoncancercenter)
Founder & President, ONCOtherapeutics
Founder & Principal, ONCOtracker
Multiple myeloma (active) is the most common type plasma cell cancer. However, the following are other forms of myeloma or myeloma-related conditions:
Monoclonal gammopathy of undetermined significance (MGUS)
Asymptomatic (smoldering/indolent) myeloma
solitary plasmacytoma of the bone
Extramedullary plasmacytoma
Light chain myeloma
Non-secretory myeloma
Osteosclerotic myeloma (POEMS syndrome)
Waldenstrom macroglobulinemia
Light chain amyloidosis
Plasma cell leukemia
Latest
Popular
Comments
Tags
Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study
February 8, 2022
IMBCR & Emory University’s Big Discovery!!!
February 7, 2022
James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center
February 6, 2022
What Is Multiple Myeloma?
January 10, 2019
Video Updates
June 26, 2018
Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients
February 16, 2011
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
March 19, 2011
Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting
November 23, 2011
Understanding Myeloma News About Secondary Cancers and Clotting
May 28, 2012
Dedication of “Determination”
June 1, 2012
accelerated; elotuzumab; infusion rate; monoclonal antibody; multiple myeloma
ASCO
B-cell maturation antigen
BCMA
Biomarker
Bortezomib
bortezomib; carfilzomib; multiple myeloma; proteasome inhibitor; relapsed; refractory
Carfilzomib
Dedication
HevyLite; immunoglobulins; multiple myeloma; outcomes
IMBCR
Kyprolis
lenalidomide
monoclonal antibodies
more is not better
Multiple Myeloma
myeloma
Overall survival
Pomalyst
proteasome inhibitors
Revlimid
Secondary Cancers
TRAF6
transplant
update
Scroll Up
February 22, 2016
0 Comments